ClinicalTrials.gg
CompletedNCT03555305Updated Nov 24, 2020Results posted

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

A Phase 1 interventional study of Insulin Glargine and Lantus in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented. The study will last at least 18 days, not including screening. Screening is required within 4 weeks prior to the start of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are native Chinese men or women. Native Chinese is defined as a participant who has both parents and all 4 grandparents of Chinese origin.
  • For females of (defined as not surgically sterilised and between menarche and 1-year ) only:

    • Negative serum pregnancy test at the time of screening.
    • Are not lactating.
    • Intend not to become pregnant during the study.
    • Are sexually inactive or have practiced a reliable method of for at least 6 weeks prior to screening.
    • Agree to continue to use a reliable method of birth control (as determined by the investigator) during the study.
  • For females not of childbearing potential, must be:

    • Surgically sterile, defined as having had a hysterectomy or bilateral oophorectomy or tubal ligation, and/or
    • Menopausal, defined as having had no menses for at least 1 year, or a plasma follicular stimulating hormone value of >40 milli-international units per milliliter (mIU/mL) and no menses for at least 6 months, unless the participant is taking hormone-replacement therapy.
  • Having fasting plasma glucose \<110 milligrams per deciliter (mg/dL) (\<6.1 millimoles per liter [mmol/L]) and 2-hour glucose level \<140 mg/dL (\<7.8 mmol/L) on the 75 grams (g) oral glucose tolerance test.
  • Have a (BMI) between 18 and 28 kilograms per meter squared (kg/m²), inclusive, at screening.
  • Are nonsmokers, have not smoked for at least 6 months prior to entering the study, and agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the duration of the study.
  • Have normal blood pressure and pulse rate at screening, as determined by the investigator.
  • Have an (ECG), at screening, considered as within normal limits by the investigator.
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Have a history of first-degree relatives known to have diabetes mellitus.
  • Have known allergies to insulin glargine or its , or related drugs, or heparin, or have a history of relevant allergic reactions of any origin.
  • Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Show evidence of infection (HIV) and/or positive human HIV antibodies.
  • Have positive surface antigen.
  • Have donated >400 mL of blood in the last 6 months or donated >100 mL within the last 30 days.
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption while resident in the clinical research unit (CRU) (1 unit = 12 ounces or 360 mL of beer; 5 ounces or 150 mL of wine; 1.5 ounces or 45 mL of distilled spirits).
  • Intend to use: prescription medication or over-the-counter medication or Chinese traditional medicine within 14 days before dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement, or methods). If this situation arises, an otherwise suitable participant may be included at the discretion of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Insulin Glargine

    Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).

    Drug: Insulin Glargine

  • Active comparator
    Lantus

    Participants received 0.5 U/Kg of Lantus subcutaneously.

    Drug: Lantus

Interventions

  • Administered SC

    Also known as: LY2963016, Basaglar

  • DrugLantus

    Administered SC

    Also known as: Insulin Glargine

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus

    Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.

    Time frame: -0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus

    PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC\[0-24\]) of Insulin glargine and Lantus.

    Time frame: -0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose

Secondary outcomes

  1. Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)

    Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

    Time frame: 30 minutes predose through 24 hours postdose

  2. PD: Maximum Glucose Infusion Rate (Rmax)

    Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

    Time frame: 30 minutes predose through 24 hours postdose

07

Results

Posted Nov 24, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2
Started2929
Received at least 1 dose of study drug2929
Completed2927
Not completed02
Withdrew: Physician decision01
Withdrew: Adverse event01
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2
Started2927
Completed2927
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus

Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.

Time frame:
-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose
Reported as:
Geometric mean · picomole per liter (pmol/L)
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus
picomole per liter (pmol/L)0.5 U/kg Insulin Glargine0.5 U/kg Lantus
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus124 ± 31129 ± 33
Statistical analysis
  • 0.5 U/kg Insulin Glargine vs 0.5 U/kg Lantus · Linear mixed-effects model · Ratio of geometric least squares means: 0.961 · 90% CI 0.886 to 1.04
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus

PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC\[0-24\]) of Insulin glargine and Lantus.

Time frame:
-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose
Reported as:
Geometric mean · picomole*hour per liter (pmol*hr/L)
PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus
picomole*hour per liter (pmol*hr/L)0.5 U/kg Insulin Glargine0.5 U/kg Lantus
PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus2170 ± 282310 ± 29
Statistical analysis
  • 0.5 U/kg Insulin Glargine vs 0.5 U/kg Lantus · Linear mixed-effects model · Ratio of geometric least squares means: 0.943 · 90% CI 0.874 to 1.02
SecondaryPharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)

Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

Time frame:
30 minutes predose through 24 hours postdose
Reported as:
Geometric mean · milligrams/kilogram (mg/kg)
Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)
milligrams/kilogram (mg/kg)0.5 U/kg Insulin Glargine0.5 U/kg Lantus
Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)2390 ± 432680 ± 40
SecondaryPD: Maximum Glucose Infusion Rate (Rmax)

Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

Time frame:
30 minutes predose through 24 hours postdose
Reported as:
Geometric mean · milligrams/kilograms/minute (mg/kg/min)
PD: Maximum Glucose Infusion Rate (Rmax)
milligrams/kilograms/minute (mg/kg/min)0.5 U/kg Insulin Glargine0.5 U/kg Lantus
PD: Maximum Glucose Infusion Rate (Rmax)2.72 ± 372.99 ± 36

Adverse events

Collected over Up to 14 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5 U/kg Insulin Glargine0/56 (0%)0/56 (0%)0/56 (0%)
0.5 U/kg Lantus0/58 (0%)0/58 (0%)0/58 (0%)

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Overall
Mean24.9 ± 2.4
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female32
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino0
Not Hispanic or Latino58
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian58
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall
China58
08

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
09

References and documents

Publications

  • Liu H, Wang F, Ji Y, Ma T, Li H, Linnebjerg H, Chua L, Tham LS, Yu Y. A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. Clin Pharmacol Drug Dev. 2021 Dec;10(12):1452-1459. doi: 10.1002/cpdd.1014. Epub 2021 Aug 19. PubMed 34410042 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Nov 2019, 13 months.

Results were first posted in Nov 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2018
First posted
Jun 13, 2018
StartActual
Sep 26, 2018
Primary completionActual
Nov 4, 2019
CompletionActual
Nov 4, 2019
Results first posted
Nov 24, 2020
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03555305
Responsible party
Sponsor
First posted
Jun 13, 2018
Start date
Sep 26, 2018
Primary completion
Nov 4, 2019
Completion
Nov 4, 2019
Results posted
Nov 24, 2020
Last update
Nov 24, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion